GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Indaptus Therapeutics Inc (NAS:INDP) » Definitions » Earnings Yield (Joel Greenblatt) %

INDP (Indaptus Therapeutics) Earnings Yield (Joel Greenblatt) % : -285.71% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Indaptus Therapeutics Earnings Yield (Joel Greenblatt) %?

Indaptus Therapeutics's Enterprise Value for the quarter that ended in Sep. 2024 was $5.37 Mil. Indaptus Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $-15.37 Mil. Indaptus Therapeutics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2024 was -285.71%.

The historical rank and industry rank for Indaptus Therapeutics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

INDP' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10000   Med: 0   Max: No Debt
Current: -322.58

During the past 4 years, the highest Earnings Yield (Joel Greenblatt) of Indaptus Therapeutics was 10000.00%. The lowest was -10000.00%. And the median was 0.00%.

INDP's Earnings Yield (Joel Greenblatt) % is ranked worse than
95.1% of 1367 companies
in the Biotechnology industry
Industry Median: -13.76 vs INDP: -322.58

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Indaptus Therapeutics's Forward Rate of Return (Yacktman) % for the quarter that ended in Sep. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Indaptus Therapeutics Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Indaptus Therapeutics's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indaptus Therapeutics Earnings Yield (Joel Greenblatt) % Chart

Indaptus Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
- -95.24 105.26 -1,000.00

Indaptus Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -222.22 -1,000.00 -166.67 -149.25 -285.71

Competitive Comparison of Indaptus Therapeutics's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Indaptus Therapeutics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Indaptus Therapeutics's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Indaptus Therapeutics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Indaptus Therapeutics's Earnings Yield (Joel Greenblatt) % falls into.



Indaptus Therapeutics Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Indaptus Therapeuticss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-16.378/1.598848
=-1,024.36 %

Indaptus Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.37 Mil.



Indaptus Therapeutics  (NAS:INDP) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Indaptus Therapeutics Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Indaptus Therapeutics's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Indaptus Therapeutics Business Description

Industry
Traded in Other Exchanges
N/A
Address
3 Columbus Circle, 15th Floor, New York, NY, USA, 10019
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
Executives
Glen R. Anderson 10 percent owner 3274 ROSS ROAD, PALO ALTO CA 94303
Roger J. Waltzman officer: Chief Medical Officer C/O JAGUAR ANIMAL HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Robert Martell director 4 MAGUIRE ROAD, LEXINGTON MA 02421
Boyan Vesselinov Litchev officer: Chief Medical Officer 13357 RUSSET LEAF LN., SAN DIEGO CA 92129
Jeffrey A Meckler director, officer: Chief Executive Officer 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
Walt Addison Linscott officer: Chief Business Officer 1860 MONTREAL ROAD, TUCKER GA 30084
Michael James Newman director, 10 percent owner, officer: Chief Scientific Officer C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512
Mark John Gilbert director 13731 NORTHWOOD RD., NW, SEATTLE WA 98177
Brian O'callaghan director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Hoonmo Lee director, 10 percent owner C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512
Anthony J Maddaluna director PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
William B Hayes director 231 MAPLE AVENUE, BURLINGTON NC 27215
Roger Pomerantz director 711 HARVEST HILL ROAD, CHALFONT PA 18914
Hila Karah director 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Nir Sassi officer: Chief Financial Officer 3 ELUL STREET, APT. 6, MODIIN L3 7176397

Indaptus Therapeutics Headlines